Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21waf1 and p27kip1

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 913-920

  Kalemi, Theodora G ^a,b   Papazisis, Konstantinos T ^b   Lambropoulos, Alexandros F ^a   Voyatzi, Soultana ^b   Kotsis, Alexandros ^a   Kortsaris, Alexandros H ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; CDK inhibitors; HER1 4; p21; p27; Receptor tyrosine kinases

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER;

EID: 34247097594     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Ullrich A, Coussens L, Hayflick JS, Dull T J, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA and Schlessinger J: Human epidermal growth factor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
2. Coussens L, Yang-Feng TL, Chen YCLE, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985.
3. Kraus MH, Issing W, Miki, T, Popescu NC and Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci 86: 9193-9197, 1989.
4. Plowman GD, Culouscou JM, Whitney GS, Green GS, Carlton GW, Foy L, Neubauer MG and Shoyab M: Ligand specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750, 1993.
5. Yarden Y and Ullrich A: Growth factor receptor tyrosine kinases. Ann Rev Biochem 57: 443-478, 1988.
6. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Bioch Bioph Res Comm 319: 1-11, 2004.
7. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
8. Hynes NE, Horsch K, Olayioye MA and Badache A: The ErbB receptor tyrosine family as signal integrators. Endocrine-Related Cancer 8: 151-159, 2001.
9. Chang H, Riese DJ, Gilbert W, Stern DF and McMahan UJ: Ligands for ErbB family receptors encoded by a neuregulin-like gene. Nature 387: 509-512, 1997.
10. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB2 the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signalling. EMBO J 16: 1647-1655, 1997.
11. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
12. Guy PM, Platko JV, Cantley LC, Cerione RA and Carraway KL: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91: 8132-8136, 1999.
13. Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48, 1998.
14. Gullick WJ: The type I growth factor receptors and their ligands considered as a complex system. Endocrine-Related Cancer 8: 75-82, 2001.
15. Burden S and Yarden Y: Neuregulins and their receptors: a versatile signalling molecule in organogenesis and oncogenesis. Neuron 18: 847-855, 1997.
16. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S and Sorvillo JM: Expression of neu protein, epidermal growth factor receptor and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. Am J Pathol 138: 1527-1534, 1991.
17. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K and Toge T: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164: 323-326, 1992.
18. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens K, Skovlund E and Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25, 2002.
19. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A and Yoshinaga SK: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271(7): 3884-3890, 1996.
20. Alroy I and Yarden Y: The ErbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86, 1997.
21. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
22. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
23. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai L, Zhang P, Dobtowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP and Wei N: Inhibition of cyclin dependent kinases by p21. Mol Biol Cell 6: 387-400, 1995.
24. Zhang H, Xiong Y and Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897-906, 1993.
25. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer WE, Kinzler K and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
26. Harper JW, Adami G, Wei N, Keyomarsi K and Elledge S: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
27. Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
28. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90-98, 1994.
29. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
30. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
31. Lee MH, Reynisdottir I and Massagué J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-649, 1995.
32. Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Baldini A, Harper J and Elledge S: p57, a structurally distinct member of the p21 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9: 650-662, 1995.
33. Dulic V, Kaufman WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclindependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
34. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
35. Brugarolas J, Chadrasekaran C, Gordon J, Beach D, Jacks T and Hannon G: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557, 1995.
36. Niculescu AR, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
37. Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17: 4877-4882, 1997.
38. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung MC: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2(5): 581-591, 1998.
39. Michels JJ, Duigou F, Marnay J, Henry-Amar M, Delozier T, Denoux Y and Chasle J: Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance. Cancer 97(6): 1376-1386, 2003.
40. Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Gene Dev 13: 1501-1512, 1999.
41. Philipp-Staheli J, Payne SR and Kemp CJ: p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264(1): 148-168, 2001.
42. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds J A, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ and Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94(12): 6380-6385, 1997.
43. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3(2): 227-230, 1997.
44. Zhang Y, Kulp SK, Sugimoto Y, Farrar W, Brueggemeier R and Lin YC: Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells. Anticancer Res 18: 2541-2546, 1998.
45. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
46. Slamon J, Clark M, Wong G, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu Oncogene. Science 235: 177-182, 1987.
47. Poon RY and Hunter T: Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells. Oncogene 16(10): 1333-1343, 1998.
48. Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RCF and Angus B: Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 56: 300-304, 2003.
49. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E and Czerwenka K: Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80: 353-361, 2003.
50. Bieche I, Onody P, Tozlu S, Driough K, Vidaud M and Lidereau R: Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106: 758-765, 2003.
51. Pawlowski V, Revillion F, Hebbar M, Hornez L and Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6: 4217-4225, 2000.
52. Bobrow LG, Millis RR, Happerfield LC and Gullick WJ: c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur J Cancer 33(11): 1846-1850, 1997.
53. Witton C, Reeves J, Going J, Cooke T and Barlett J: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Path 200: 290-297, 2003
54. Srinivasan R, Poulsom R, Hurst HC and Gullick WJ: Expression of the c-erbB-4/HER-4 protein and mRNA expression in normal human fetal and adult tissues and in a survey of nine solid tumor type. J Pathol 185: 236-245, 1998.
55. Klijn JGM, Berns PMJJ, Schmitz PIM and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review of 5232 patients. Endocr Rev 13: 3-17, 1992.
56. Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10: 3815-3824, 2004.
57. Waf1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 5(6): 242-249, 2003.
58. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252, 2001.
59. Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC and Lee MH: Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcin 30(3): 169-175, 2001.
60. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS and Goldhirsch A: Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 97(7): 1591-1600, 2003.
61. Prigent SA and Gullick WJ: Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13(12): 2831-2841, 1994.
62. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H and Sun H: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 11: 263-267, 2001.
63. Moelling K, Schad K, Bosse M, Zimmermann S and Schweneker M: Regulation of Raf-Akt Cross-talk. J Biol Chem 277(34): 31099-31106, 2002.